Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series.
Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series.
复制标题
DOI：
10.1002/jbmr.1749
复制
发表时间：
2013-02
影响因子：
6.2
通讯作者：
Vessella, Robert L.
中科院分区：
文献类型：
--
作者：
Morrissey, Colm;Roudier, Martine P.;Dowell, Alex;True, Lawrence D.;Ketchanji, Melanie;Welty, Christopher;Corey, Eva;Lange, Paul H.;Higano, Celestia S.;Vessella, Robert L.
对44例抗去势前列腺癌(CRPC)患者(其中一些患者在雄激素剥夺治疗(ADT)的基础上加用双膦酸类药物(BP)治疗)的20个预定部位的未脱钙和脱钙骨进行了定性和定量的骨特征测定。44例患者中有39例(%)有骨转移的证据。通过组织形态计量学分析，这些骨转移与从成骨到溶骨的一系列骨反应有关，通常在单个患者中可以看到广泛的骨反应。总体而言，平均骨体积/组织体积(BV/TV)为25.7%，与正常年龄匹配的加权平均BV/TV 14.7%相比，证实了成骨反应与前列腺癌骨转移的特征相关。观察到的新骨形成本质上是编织骨，这是一种局部性事件。比较接受BP治疗和未接受BP治疗的患者转移部位的BV/TV，差异有统计学意义(分别为28.6%和19.3%)。在未受肿瘤侵袭的骨部位，平均BV/TV为10.1%，表明ADT导致的骨丢失在接受BPS治疗的患者中没有改善(11%)。令人惊讶的是，在接受BPS治疗和未接受BPS治疗的患者之间，转移部位存在的破骨细胞数量没有显著差异，但在接受BPS治疗的患者的骨部位，观察到巨大的破骨细胞。总共分析了873个石蜡包埋样品和661个甲基丙烯酸甲酯包埋样品。我们的结果表明，在CRPC患者中，ADT即使在BP治疗的患者中也会导致严重的骨丢失。此外，在这组患者中，与没有接受BP治疗的患者相比，BP治疗增加了前列腺癌骨转移中的BV，并且没有减少破骨细胞的数量。
Qualitative and quantitative bone features were determined in nondecalcified and decalcified bone from 20 predetermined bone sites in each of 44 patients who died with castration resistant prostate cancer (CRPC), some of which received bisphosphonate treatment (BP) in addition to androgen deprivation therapy (ADT). Thirty nine of the 44 patients (89%) had evidence of bone metastases. By histomorphometric analysis, these bone metastases were associated with a range of bone responses from osteoblastic to osteolytic with a wide spectrum of bone responses often seen within an individual patient. Overall, the average bone volume/tissue volume (BV/TV) was 25.7% confirming the characteristic association of an osteoblastic response to prostate cancer bone metastasis when compared to the normal age-matched weighted mean BV/TV of 14.7%. The observed new bone formation was essentially woven bone and this was a localized event. In comparing BV/TV at metastatic sites between patients who had received BP treatment and those that had not, there was a significant difference (28.6% vs 19.3%, respectively). At bone sites that were not invaded by tumor, the average BV/TV was 10.1% indicating significant bone loss due to ADT that was not improved (11%) in those patients who had received BPs. Surprisingly there was no significant difference in the number of osteoclasts present at the metastatic sites between patients treated or not treated with BPs but in bone sites where the patient had been treated with BPs, giant osteoclasts were observed. Overall, 873 paraffin embedded specimens and 661 methylmethacrylate embedded specimens were analyzed. Our results indicate that in CRPC patients, ADT induces serious bone loss even in patients treated with BP. Furthermore, in this cohort of patients, BP treatment increased BV and did not decrease the number of osteoclasts in prostate cancer bone metastases compared to bone metastases from patients who did not receive BP.
登录
查看更多内容
影响因子：
3.3
作者：
Roudier, MP;True, LD;Vessella, RL
通讯作者：
Vessella, RL
影响因子：
4.8
作者：
Glantschnig, Helmut;Hampton, Richard A.;Wang, Fubao
通讯作者：
Wang, Fubao
DOI：
10.1056/nejmoa0802633
发表时间：
2009-01-01
期刊：
The New England journal of medicine
影响因子：
--
作者：
Weinstein RS;Roberson PK;Manolagas SC
通讯作者：
Manolagas SC
影响因子：
11.5
作者：
Coleman, Robert E.
通讯作者：
Coleman, Robert E.
DOI：
10.1016/j.juro.2008.04.140
发表时间：
2008-09
期刊：
The Journal of urology
影响因子：
--
作者：
Roudier MP;Morrissey C;True LD;Higano CS;Vessella RL;Ott SM
通讯作者：
Ott SM